Acute administration of epirubicin induces myocardial depression in isolated rat heart and production of radical species evaluated by electron spin resonance spectroscopy

Journal of Cardiovascular Pharmacology

Volumn 50, Issue 6, 2007, Pages 647-653

  Delemasure, Stéphanie ^a   Sicard, Pierre ^a   Lauzier, Benjamin ^a   Moreau, Daniel ^a   Vergely, Catherine ^a   Rochette, Luc ^a  

^a UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

Electron spin resonance spectroscopy; Epirubicin; Isolated perfused rat heart; Isoproterenol; Reactive oxygen nitrogen species

Indexed keywords

1 HYDROXY 3 CARBOXYPYRROLIDINE; ANTHRACYCLINE ANTIBIOTIC AGENT; EPIRUBICIN; ISOPRENALINE; LACTATE DEHYDROGENASE; PYRROLIDINE DERIVATIVE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DRUG EFFECT; ELECTRON SPIN RESONANCE; ENZYME RELEASE; HEART DENERVATION; HEART FUNCTION TEST; HEART LEFT VENTRICLE PRESSURE; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STATISTICAL SIGNIFICANCE;

ANALYSIS OF VARIANCE; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CORONARY CIRCULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRON SPIN RESONANCE SPECTROSCOPY; EPIRUBICIN; FREE RADICALS; HEART; HEART RATE; ISOPROTERENOL; L-LACTATE DEHYDROGENASE; MALE; MOLECULAR STRUCTURE; MYOCARDIUM; OXIDATIVE STRESS; PERFUSION; RATS; RATS, WISTAR; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES; TIME FACTORS; VENTRICULAR FUNCTION, LEFT;

EID: 37349084565     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31815571f7     Document Type: Article

References (42)

1. Weiss RB. The anthracyclines: will we ever find a better doxorubicin? Semin Oncol. 1992;19:670-686.
2. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med. 1996;125:47-58.
3. Wojtacki J, Lewicka-Nowak E, Lesniewski-Kmak K. Anthracycline-induced cardiotoxicity: clinical course, risk factors, pathogenesis, detection and prevention-review of the literature. Med Sci Monit. 2000;6:411-420.
4. Minotti G, Menna P, Salvatorelli E, et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56:185-229.
5. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97:2869-2879.
6. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710-717.
7. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998;339:900-905.
8. Nousiainen T, Jantunen E, Vanninen E, et al. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Br J Cancer. 2002;86:1697-1700.
9. Alderton PM, Gross J, Green MD. Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model. Cancer Res. 1992;52:194-201.
10. Fumoleau P, Roche H, Kerbrat P, et al. Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results. Ann Oncol. 2006;17:85-92.
11. Olson RD, Mushlin PS. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. Faseb J. 1990;4:3076-3086.
12. Horenstein MS, Vander Heide RS, L'Ecuyer TJ. Molecular basis of anthracycline-induced cardiotoxicity and its prevention. Mol Genet Metab. 2000;71:436-444.
13. Piazza E, Natale N, Trabattoni A, et al. Plasma and tissue distribution of adriamycin in patients with pelvic cancer. Tumori. 1981;67:533-537.
14. Gambert S, Vergely C, Filomenko R, et al. Adverse effects of free fatty acid associated with increased oxidative stress in postischemic isolated rat hearts. Mol Cell Biochem. 2006;283:147-152.
15. Pouna P, Bonoron-Adele S, Gouverneur G, et al. Evaluation of anthracycline cardiotoxicity with the model of isolated, perfused rat heart: comparison of new analogues versus doxorubicin. Cancer Chemother Pharmacol. 1995;35:257-261.
16. Joyeux M, Godin-Ribuot D, Faure P, et al. Heat stress protects against electrophysiological damages induced by acute doxorubicin exposure in isolated rat hearts. Cardiovasc Drugs Ther. 2001;15:219-224.
17. Kizaki K, Akatsuka K, Momozaki M, et al. Changes in myocardial beta 1-adrenergic receptor and stimulatory G-protein gene expression after chronic treatment with doxorubicin in rat. J Vet Med Sci. 2004;66:989-992.
18. Vergely C, Tabard A, Maupoil V, et al. Isolated perfused rat hearts release secondary free radicals during ischemia reperfusion injury: cardiovascular effects of the spin trap alpha-phenyl N-tert-butylnitrone. Free Radic Res. 2001;35:475-489.
19. Oudot A, Martin C, Busseuil D, et al. NADPH oxidases are in part responsible for increased cardiovascular superoxide production during aging. Free Radic Biol Med. 2006;40:2214-2222.
20. Dikalov S, Skatchkov M, Bassenge E. Spin trapping of superoxide radicals and peroxynitrite by 1-hydroxy-3-carboxy-pyrrolidine and 1-hydroxy-2,2,6, 6-tetramethyl-4-oxo-piperidine and the stability of corresponding nitroxyl radicals towards biological reductants. Biochem Biophys Res Commun. 1997;231:701-704.
21. Robert J. Epirubicin. Clinical pharmacology and dose-effect relationship. Drugs. 1993;45 Suppl 2:20-30.
22. Calderone A, de Champlain J, Rouleau JL. Adriamycin-induced changes to the myocardial beta-adrenergic system in the rabbit. J Mol Cell Cardiol. 1991;23:333-342.
23. de Jong J, Schoofs PR, Onderwater RC, et al. Isolated mouse atrium as a model to study anthracycline cardiotoxicity: the role of the beta-adrenoceptor system and reactive oxygen species. Res Commun Chem Pathol Pharmacol. 1990;68:275-289.
24. Kusuoka H, Futaki S, Koretsune Y, et al. Alterations of intracellular calcium homeostasis and myocardial energetics in acute adriamycin-induced heart failure. J Cardiovasc Pharmacol. 1991;18:437-444.
25. Nagami K, Yoshikawa T, Suzuki M, et al. Abnormal beta-adrenergic transmembrane signaling in rabbits with adriamycin-induced cardiomyopathy. Jpn Circ J. 1997;61:249-255.
26. Xu MF, Tang PL, Qian ZM, et al. Effects by doxorubicin on the myocardium are mediated by oxygen free radicals. Life Sci. 2001;68:889-901.
27. Gnanapragasam A, Yogeeta S, Subhashini R, et al. Adriamycin induced myocardial failure in rats: protective role of Centella asiatica. Mol Cell Biochem. 2007;294:55-63.
28. Hershko C, Link G, Tzahor M, et al. Anthracycline toxicity is potentiated by iron and inhibited by deferoxamine: studies in rat heart cells in culture. J Lab Clin Med. 1993;122:245-251.
29. Dalloz F, Maingon P, Cottin Y, et al. Effects of combined irradiation and doxorubicin treatment on cardiac function and antioxidant defenses in the rat. Free Radic Biol Med. 1999;26:785-800.
30. Davies KJ, Doroshow JH. Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. J Biol Chem. 1986;261:3060-3067.
31. Doroshow JH. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res. 1983;43:460-472.
32. Fogli S, Nieri P, Breschi MC. The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. Faseb J. 2004;18:664-675.
33. Weinstein DM, Mihm MJ, Bauer JA. Cardiac peroxynitrite formation and left ventricular dysfunction following doxorubicin treatment in mice. J Pharmacol Exp Ther. 2000;294:396-401.
34. Vasquez-Vivar J, Martasek P, Hogg N, et al. Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. Biochemistry. 1997;36:11293-11297.
35. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol. 1996;271:C1424-1437.
36. Pacher P, Liaudet L, Bai P, et al. Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation. 2003;107:896-904.
37. Meinardi MT, Gietema JA, van Veldhuisen DJ, et al. Long-term chemotherapy-related cardiovascular morbidity. Cancer Treat Rev. 2000;26:429-447.
38. Kalay N, Basar E, Ozdogru I, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2006;48:2258-2262.
39. Delemasure S, Vergely C, Zeller M, et al. Preventing the cardiotoxic effects of anthracyclins. From basic concepts to clinical data.. Ann Cardiol Angeiol (Paris). 2006;55:104-112.
40. Pouillart P. Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines. Cancer Treat Rev. 2004;30:643-650.
41. Von Hoff DD, Howser D, Lewis BJ, et al. Phase I study of ICRF-187 using a daily for 3 days schedule. Cancer Treat Rep. 1981;65:249-252.
42. Hou G, Dick R, Abrams GD, et al. Tetrathiomolybdate protects against cardiac damage by doxorubicin inmice. J Lab Clin Med. 2005;146:299-303.